Because the COVID-19 pandemic is negatively affecting the overall volume of diagnostic imaging procedures, the pandemic will have a significant impact on the European contrast agent and radiopharmaceutical market in the short term. Once the situation improves, the European contrast agent and radiopharmaceutical market will resume slow growth through 2029, driven by rising radiopharmaceutical ASPs and increasing demand for diagnostic imaging procedures for Europe's aging population, although the market will be hindered to some extent by stringent reimbursement regulations and the ongoing safety controversy surrounding GBCAs.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for contrast agents and radiopharmaceuticals in Europe across a 10-year period.
The COVID-19 pandemic will affect the contrast agent and radiopharmaceutical market.
To what extent will the COVID-19 pandemic impact the European contrast agent and radiopharmaceutical market?
How will the impact of the COVID-19 pandemic differ between segments?
How quickly are procedure volumes expected to rebound?
Recent studies have questioned the safety of GBCAs.
How has the EMA responded to studies that call into question the safety of GBCAs?
To what extent will these studies impact the MRI contrast agent market through 2029?
How can competitors best respond to these safety concerns such that the impact on their products and revenues can be minimized?
Global fluctuations in the supply of Mo-99—the key isotope in the production of Tc for use in most SPECT procedures—will continue to negatively impact the market going forward.
To what extent will supply limitations affect revenue growth in the European SPECT radiopharmaceutical market?
Less contrast material is being used per patient procedure in Europe.
What are some of the key factors driving this trend?
What novel technology will contribute to this trend in the future?
Which markets will be the most impacted by this shift in usage?
The European market is more competitive compared to the US market.
What are the key factors end users look for in a product?
How do local competitors fare compared to MNCs in the European contrast agent and radiopharmaceutical market?
How can smaller companies best position themselves to garner more market share going forward?
- Contrast Agents And Radiopharmaceuticals - Market Insights - Europe
Author(s): Vijjapu Kameswara Rao, MS Pharm
Vijjapu Kameswara Rao is a research associate on the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at DRG (Part of Clarivate), specializing in the gynecological device market. Kamesh holds a Bachelor's degree in Pharmaceutical Sciences from the Jawaharlal Nehru Technological University Kakinada and a Master's degree in Pharmaceutical Analysis from the National Institute of Pharmaceutical Education and Research, Mohali.